Loading...
•
Sep 30, 2024
BD Q4 2024 Earnings Report
BD reported strong growth and margin execution, driving performance in Q4 2024.
Key Takeaways
BD reported Q4 revenue of $5.4 billion, a 6.9% increase as reported. GAAP EPS grew 173.6% to $1.45, and adjusted EPS grew 11.4% to $3.81. The company issued FY25 adjusted diluted EPS guidance of $14.25 to $14.60, reflecting growth of about 10% at the midpoint.
Q4 revenue increased 6.9% as reported, 7.4% currency-neutral and 6.2% organic.
Q4 GAAP and adjusted diluted EPS from continuing operations grew 173.6% and 11.4%, respectively.
FY24 cash from continuing operations grew 28.5% to $3.8 billion.
Company issues FY25 revenue guidance including GAAP growth of 8.9% to 9.4%, adjusted currency-neutral growth of 8.8% to 9.3% and organic growth of 4.0% to 4.5%.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The company provided the following guidance with respect to fiscal 2025. GAAP revenue growth of 8.9% to 9.4% and currency-neutral adjusted revenue growth of 8.8% to 9.3% include the newly acquired APM business. The company's organic revenue growth guidance of 4.0% to 4.5% includes absorbing an impact about 125 basis points from an expected decline in revenues in China and Bioscience and Pharma market dynamics.
Positive Outlook
- GAAP Revenues ~$21.9 to $22.1 billion
- GAAP Revenue Growth 8.9% to 9.4%
- Adjusted Revenue Growth (FXN) 8.8% to 9.3%
- Organic Revenue Growth (FXN) 4.0% to 4.5%
- Adjusted Diluted EPS $14.25 to $14.60
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...